Cachexia remains one of the most challenging complications in oncology, characterized by profound muscle wasting, energy imbalance, and ultimately severe functional decline. Despite its clinical significance, the systemic nature of this syndrome, involving skeletal muscle, adipose tissue, liver, and beyond, has complicated efforts to decode its molecular logic. The research led by Morigny and colleagues marks a paradigm shift by leveraging multi-omics — integrating transcriptomics, proteomics, and metabolomics — to characterize temporal and spatial molecular alterations in tissues targeted by cachexia during tumor progression.

One of the key revelations of this study is the dynamic interplay between tissues at different stages of disease, highlighting how cachexia evolves as a coordinated systemic response rather than isolated tissue dysfunction. By longitudinally profiling murine models bearing cachexia-inducing tumors, distinct patterns of inflammatory pathways, metabolic reprogramming, and signaling cascades were mapped with remarkable resolution. These data unveil how early perturbations in energy metabolism gradually propagate, instigating widespread catabolic remodeling across muscle and fat depots.

From a technical standpoint, the authors employed high-throughput RNA sequencing to capture global transcriptome shifts, while advanced mass spectrometry-based proteomics provided complementary insights into protein abundance and modifications. Moreover, metabolomic profiling unraveled alterations in bioenergetic intermediates and lipid species that signify disrupted metabolic homeostasis. The rigorous integration of these datasets via sophisticated bioinformatics pipelines allowed the team to identify molecular signatures that predict progression from pre-cachectic to full cachectic states, representing an invaluable resource for biomarker discovery.

The spatial dimension of their analysis is especially noteworthy. Using tissue-specific multi-omics, the study elucidated how cachexia manifests heterogeneously among individual organs over time. For instance, early mitochondrial dysfunction and oxidative stress signatures in skeletal muscle presage later widespread proteolysis and atrophy, while adipose tissue exhibits a distinctive lipolytic and inflammatory profile that evolves distinctly but contributes to systemic energy depletion. These findings underscore the necessity of considering temporal tissue crosstalk when designing anti-cachexia strategies.

Importantly, this comprehensive molecular atlas also identified key regulatory nodes amenable to pharmacological targeting. Several signaling pathways implicated in muscle degradation — including NF-kB and ubiquitin-proteasome mechanisms — showed coordinated activation with metabolic rewiring in adipose tissue, suggesting synergy in cachexia pathogenesis. This integrated perspective uncovers opportunities to disrupt maladaptive inter-organ communication and restore metabolic balance, heralding a new era of multi-targeted precision therapies.

The experimental design incorporated both early- and late-stage cancer models, enabling the investigation of how tumor-derived factors orchestrate systemic changes from initial insult through established cachexia. Notably, distinct secretome profiles were linked to specific cachectic phenotypes, supporting the notion that tumor heterogeneity influences metabolic outcomes differently. These data emphasize the clinical importance of personalized approaches to cachexia management based on tumor biology and patient metabolic status.

In addition to revealing pathogenetic mechanisms, the study provides a robust framework for future research, incorporating multi-omics as a standard toolset to dissect complex systemic syndromes. Such approaches hold promise beyond cachexia, including other metabolic disorders where organ crosstalk and temporal evolution play critical roles. As multi-omics technologies continue to advance in sensitivity and throughput, integrating these data with longitudinal clinical monitoring will accelerate biomarker identification and therapeutic innovation.

Given the staggering global burden of cancer-associated cachexia, translating these insights into clinical applications is urgent. The identification of early molecular signatures predictive of cachexia onset may enable timely interventions to halt or mitigate muscle wasting and metabolic decline. Furthermore, multi-omics data pave the way for biomarker-guided clinical trials of novel therapeutics targeting key pathways influencing tissue crosstalk and systemic inflammation.

The study also highlights the importance of considering sex differences, hormonal influences, and microenvironmental variables within the cachexia phenotype. Future investigations could extend the multi-omic paradigm to incorporate epigenomic and single-cell resolution data, further refining our understanding of cellular contributors and heterogeneity within affected tissues. This integrative systems biology approach is vital for uncovering the multilayered complexity of cachexia.

In summary, Morigny et al. provide an unprecedented, holistic examination of the spatio-temporal molecular networks driving cancer cachexia. Their multi-omics profiling clarifies how tumors induce a coordinated systemic catabolic response impacting multiple organs, unveiling novel mechanistic insights and therapeutic targets. This comprehensive dataset represents a milestone in cachexia research, empowering translational efforts to improve quality of life and survival for cancer patients suffering from this debilitating syndrome.

As the field marches forward, integrating such multi-dimensional biological information will be crucial for developing precision metabolic therapies. The coordinated tissue-specific molecular atlas generated by Morigny and colleagues sets new standards for mechanistic research into systemic syndromes and will undoubtedly inspire a generation of studies exploiting multi-omics to conquer cachexia and related metabolic diseases.

With this work, cancer cachexia emerges not merely as a late-stage byproduct of malignancy but as a complex, orchestrated disease process amenable to early detection and intervention. These revelations invigorate hope for biomarker-driven strategies that transform clinical management paradigms, alleviating the heavy toll of cachexia on patients and healthcare systems worldwide.

Morigny and collaborators’ landmark contribution underscores the power of multi-omics integration to decode biological complexity in human disease. Their ability to map the temporal sequence of molecular events across organs heralds a new era of systems-level oncology research, where precision understanding of tumor-host interactions will guide therapeutic innovation. The dawn of multi-omics-enabled cachexia research promises profound impact on cancer care, helping unlock resilience in the face of metabolic despair.

The elegance and depth of this study exemplify how cutting-edge technologies are reshaping our understanding of disease biology. By charting the molecular choreography underpinning cachexia, Morigny et al. provide a blueprint for decoding other multifactorial metabolic disorders. As clinical translation progresses, it is essential to harness these integrative scientific insights to improve patient outcomes and foster new hope against cancer-induced metabolic decline.

Morigny’s multi-omics approach places the cachexia research community on a transformative trajectory, elucidating complexity through high-dimensional datasets synergistically analyzed across space and time. The future of cachexia research lies in such meticulous, system-wide interrogations, revealing actionable pathways concealed within disorder complexity. As these findings ripple through clinical and preclinical arenas, they promise to catalyze impactful breakthroughs with enduring clinical benefit.

Subject of Research: Multi-omics profiling of cachexia-targeted tissues in cancer

Article Title: Multi-omics profiling of cachexia-targeted tissues reveals a spatio-temporally coordinated response to cancer

Article References:
Morigny, P., Vondrackova, M., Ji, H. et al. Multi-omics profiling of cachexia-targeted tissues reveals a spatio-temporally coordinated response to cancer. Nat Metab (2026). https://doi.org/10.1038/s42255-025-01434-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01434-3

The investigation began with a focus on how certain tastes, such as sweetness, trigger the compulsion to keep eating beyond physiological need. While we know that sweet flavors can stimulate appetite, researchers had struggled to identify the specific neural mechanisms that transform taste perception into the complex drive to consume. Using advanced neuroanatomical and optogenetic techniques, the team traced the pathway from sugar-sensitive neurons in the amygdala — the brain’s emotion center involved in evaluating pleasurable stimuli — to a lesser-known brain region called the bed nucleus of the stria terminalis (BNST).

Neurons in the central amygdala that responded selectively to sweet stimuli were found to project directly into the BNST, a structure historically implicated in processing stress and reward, but not previously understood to have a broad modulatory role in feeding behavior. When the researchers used targeted stimulation to activate these BNST neurons, mice that had recently eaten to fullness began consuming sweets again, indicating that this circuit can override satiety cues. Conversely, inhibiting the BNST neurons resulted in reduced sugar intake, even in hungry animals, demonstrating that this brain area acts as a powerful control point for consumption.

Further experiments expanded the scope of this neural “brain dial.” It was revealed that the BNST does not merely regulate sweet intake but is also essential for driving the consumption of salt, fats, and other palatable food components. This generalist role contrasts with many other brain circuits that respond selectively to specific tastes or food types, highlighting the BNST as a hub for coordinating a wide range of consummatory behaviors. Such integration ensures that animals can adjust their eating based both on sensory inputs and physiological needs.

The anatomical underpinnings of the BNST’s function are equally fascinating. Beyond connections with taste-processing regions, the BNST communicates extensively with brain systems involved in sensing internal states, such as hunger or electrolyte balance. For example, the region is linked to circuits that detect sodium deficiency, which triggers salt craving. This neural network enables the brain to harmonize external sensory information with internal bodily demands, fine-tuning feeding behavior to maintain homeostasis.

This discovery has profound implications for medical science, especially for patients undergoing chemotherapy who frequently develop cachexia, a debilitating condition marked by appetite loss and muscle wasting. In mouse models treated with chemotherapy drugs that induce a similar cachexia-like state, activating BNST neurons was found to preserve body weight and protect against the expected decline in consumption. These findings raise the exciting possibility that targeted stimulation of this brain circuit could alleviate cachexia symptoms, improving quality of life and treatment outcomes for cancer patients.

Moreover, the researchers noted that BNST neurons are a target of semaglutide, a widely used anti-obesity drug known to suppress appetite but also associated with adverse effects such as nausea. By elucidating the role of the BNST in appetite regulation, this work paves the way for developing more precise therapeutic strategies that modulate consummatory behavior without undesirable side effects. A refined understanding of the BNST might enable the design of interventions that better balance efficacy and tolerability.

Dr. Charles S. Zuker, the senior author and a leading figure in neurobiology, emphasized that this study “provides exciting new insights and identifies a brain center that orchestrates unified control over consummatory behaviors.” He highlighted that understanding the brain’s integration of sensory pleasure and internal physiological needs could revolutionize approaches to treating both overconsumption and wasting disorders.

Co-lead author Dr. Li Wang reflected on the unexpected breadth of the BNST’s influence, noting, “We did not anticipate this brain region to be so important and involved with such a broad range of consummatory behaviors in such a general way.” This insight underscores the complexity of neural circuits regulating feeding, where a single brain hub can modulate diverse dietary urges.

The collaborative study also involved Dr. José A. Cánovas, who pointed out the significance of the BNST’s connections with internal state sensing pathways. “We now have a better understanding of how the brain integrates specific internal needs with sensory signals in order to elicit appropriate consummatory responses,” he explained. This integrative function is essential for maintaining energy balance and survival.

From a technical perspective, the team employed cutting-edge methods including optogenetics to selectively manipulate neuronal activity in live animals, as well as advanced anatomical tracing techniques to map BNST connectivity. The combination of behavioral assays and neurophysiological recordings provided a comprehensive picture of both structure and function in this critical brain circuit.

Published on September 10, 2025, this study stands to reshape our understanding of appetite and its neural regulation. The researchers candidly acknowledge that while these findings in mice open new avenues, translating such insights into human therapies will require further research, particularly given the complexity of human eating behaviors and neurological structures.

Nonetheless, this work represents a seminal step towards harnessing brain circuitry to tackle some of the most challenging health issues related to nutrition — from obesity epidemics to catastrophic weight loss in disease. By revealing a “brain dial” that can be turned up or down to regulate food consumption, the study invites a new era of neuroscience-informed dietary interventions.

Subject of Research: Animals
Article Title: A Brain Center that Controls Consummatory Responses
News Publication Date: 10-Sep-2025
Web References: https://doi.org/10.1016/j.cell.2025.08.021
References:

• Cánovas, J.A., Wang, L., Mohamed, A.A.M., Abbott, L.F., & Zuker, C.S. (2025). A Brain Center that Controls Consummatory Responses. Cell.
  Image Credits: Li Wang and José Cánovas / Zuker lab / Columbia’s Zuckerman Institute
  Keywords: Dietetics, Feeding Behavior, Neuroscience, Appetite Regulation, Brain Circuits

Cachexia presents a formidable clinical challenge, particularly prevalent in pancreatic cancer patients, where it manifests as a multifactorial wasting condition characterized by profound loss of skeletal muscle and adipose tissue. What distinguishes cachexia from simple starvation is its complexity; it is driven by both diminished appetite and metabolic disturbances orchestrated by tumor-host interactions. Understanding this syndrome’s mechanisms is critical, considering that approximately 80% of pancreatic cancer patients succumb to cachexia, which drastically reduces their quality of life and complicates therapeutic interventions.

Arreola’s doctoral research focuses on unraveling a specific molecular communication pathway through which the pancreatic tumor induces cachexia early in disease progression. His investigations center around a signaling molecule secreted by the tumor that targets a receptor localized exclusively in a discrete region of the brain stem. Intriguingly, this receptor acts as a master regulator, orchestrating the onset of muscle and fat wasting without direct involvement from the peripheral tissues themselves. This neurobiological axis effectively rewires systemic energy metabolism, triggering catabolic pathways that lead to tissue degradation.

This novel insight reveals how tumors can manipulate central nervous system circuits to subvert normal homeostatic controls. Typically, this brain stem region modulates the body’s fight-or-flight response, mobilizing energy reserves during acute stress by breaking down muscle protein and fat stores. However, the tumor hijacks this primitive survival mechanism, inducing chronic and inappropriate catabolism that results in cachexia. This distortion of physiological signaling epitomizes the insidious ways cancer disrupts systemic biology beyond mere tumor growth.

Building upon this mechanistic groundwork, Arreola’s planned postdoctoral studies will extend his lens to the liver, another key organ in systemic energy regulation and frequently a site of pancreatic cancer metastasis. The liver plays a central role in maintaining energy homeostasis through carbohydrate, lipid, and protein metabolism. By elucidating how the tumor remotely influences hepatic function, Arreola aims to parse additional pathways by which pancreatic cancer orchestrates cachexia, potentially uncovering novel therapeutic targets to preserve muscle and fat mass.

This research is poised to reshape our understanding of tumor-host communication in cachexia, highlighting the importance of central nervous system involvement and distant organ crosstalk. By focusing on the tumor-derived molecular signals and their systemic impact, Arreola’s work bridges oncology, neurobiology, and metabolism—fields that traditionally operated in isolation. The multidisciplinary nature of his approach exemplifies contemporary cancer research’s shift toward integrated systems biology.

Professor Min Li, Arreola’s mentor and associate director for global oncology at the OU Health Stephenson Cancer Center, praises his protégé’s dedication and scientific rigor. She emphasizes that this grant award both recognizes his exceptional promise and equips him to advance the field significantly. Such endorsements underscore the importance of investing in early-career researchers who innovate at the intersection of fundamental biology and clinical need.

Beyond scientific motivations, Arreola’s pursuit of cancer research is deeply personal. Having witnessed the devastating impact of pancreatic cancer on his father, he is driven by a profound desire to contribute meaningfully to this challenging field. This personal connection fuels his commitment to scientific discovery with the hope that his findings might one day translate into interventions that alleviate suffering for patients facing similar battles.

Arreola also values the collaborative ethos fostered within the academic health system, where laboratory discoveries align closely with clinical care. This unique environment enables translational research pipelines, wherein benchside hypotheses can rapidly inform bedside treatments. While he is not directly involved in patient care, the potential for his laboratory findings to inform novel drug development is a source of immense professional fulfillment.

Cachexia remains a critical unmet medical need, with current treatment options largely palliative and ineffective at reversing muscle and fat loss. By elucidating the neural and hepatic pathways through which tumors propagate cachexia, Arreola’s research could inform the development of targeted therapies that disrupt these pathways, ultimately improving patient outcomes and survival rates.

The NCI Predoctoral to Postdoctoral Fellow Transition (F99/K00) grant supporting this work is specially designed to facilitate the transition of outstanding Ph.D. candidates into independent cancer researchers. It provides a structured framework enabling researchers like Arreola to pursue ambitious projects addressing fundamental cancer biology questions while preparing for future leadership roles in the scientific community.

The University of Oklahoma Health Sciences Center, with its diverse health profession colleges and a robust research infrastructure, offers fertile ground for such transformative research endeavors. By nurturing talent through competitive funding and mentorship, the institution strengthens its role as a prominent cancer research hub within the United States.

Arreola’s groundbreaking exploration into the molecular crosstalk between pancreatic tumors, the brain stem, and the liver not only illuminates the complex etiology of cachexia but also signifies an important stride toward personalized, mechanism-based therapies for pancreatic cancer patients. As he progresses from his doctoral studies into postdoctoral research, the scientific community awaits the potential breakthroughs his work promises to deliver.

Subject of Research: Mechanisms of cachexia in pancreatic cancer, focusing on tumor-brain stem-liver communication pathways.

Article Title: University of Oklahoma Ph.D. Candidate Alex Arreola Receives National Cancer Institute Grant to Investigate Cachexia Mechanisms in Pancreatic Cancer

Web References:
http://www.ouhsc.edu

Image Credits: University of Oklahoma

Keywords: Cachexia, Pancreatic cancer, Doctoral students, Cancer metabolism, Neurobiology, Tumor-host interaction

Janowitz’s insights, articulated in his forthcoming essay titled Of Hope from Fading Will: Interoceptive Signaling and the Behavioral Biology of Cachexia published in Neuron, probe the intricate interplay between the brain and immune system that underpins this syndrome. At the heart of the essay lies a personal narrative—the words of Janowitz’s late mother, who, in the throes of cachexia, expressed herself as “all used up” with “no will left to live.” These deeply human reflections underscore the clinical urgency of understanding cachexia beyond mere metabolic deterioration.

Cachexia’s pathophysiology has traditionally been viewed through the lens of peripheral tissue wasting and inflammation. However, emerging research, including that spearheaded by Janowitz and colleagues, is positioning the syndrome within a neurobiological framework. This framework emphasizes the role of interoceptive signaling—the brain’s ability to perceive and integrate signals from internal bodily states—in driving the profound behavioral changes observed in cachectic patients, including reduced appetite, fatigue, and diminished motivation.

The essay highlights novel experimental evidence revealing that immune system dysregulation impacts specific neural circuits, particularly those involved in motivation and reward processing. This finding pivots the paradigm from viewing cachexia simply as a consequence of metabolic imbalance to recognizing it as a syndrome wherein neural pathways modulate behavioral outputs in response to systemic inflammation. Such advancements have profound implications for therapeutic interventions, suggesting that targeting neuroimmune interactions may alleviate both physiological and psychological distress in affected patients.

Janowitz’s work advocates for a paradigm shift in cancer research, urging oncologists, neuroscientists, and immunologists to merge their expertise. This interdisciplinary approach aims to decode the complex signaling cascades between the immune system and the brain that precipitate cachexia. By embracing patient-reported symptoms as vital data rather than anecdotal afterthoughts, researchers can glean insights into the subjective experience of disease and tailor treatments that address not only physical wasting but the erosion of willpower and quality of life.

From a clinical perspective, the syndrome significantly diminishes survival probabilities and complicates therapeutic regimens in cancer care. Cachexia’s impact extends beyond muscle atrophy, exacerbating treatment resistance and undermining patients’ capacity to engage with life-prolonging therapies. Therefore, understanding the neurobehavioral mechanisms that drive symptomology is imperative for designing holistic treatment protocols that integrate metabolic, immunological, and neurological targets.

The essay also casts light on the importance of interoceptive networks—neural systems that monitor and interpret physiological states such as hunger, pain, and fatigue—and their disruption in cachexia. Janowitz discusses how aberrant signaling within these networks precipitates the loss of appetite and generalized malaise, common features of the syndrome. These findings illuminate how central nervous system dysfunction contributes to the multifaceted clinical phenotype, unveiling potential biomarkers and therapeutic entry points.

Importantly, Janowitz’s narrative underscores the criticality of patient-centered science. The poignant account of his mother’s experience bridges the gap between empirical research and lived reality, reminding the scientific community that behind every data point lies a human story. This empathetic lens challenges researchers to reframe symptoms like fatigue and anorexia as informative signals guiding the understanding of disease progression and patient well-being.

The call for collaborative research efforts is complemented by the identification of promising avenues for pharmacological intervention. Modulating neuroimmune pathways, potentially through targeting pro-inflammatory cytokines or neural receptors involved in motivational drive, represents a frontier in cachexia treatment. Such strategies could revitalize patient will, improving both physical resilience and psychological state.

Moreover, this evolving comprehension of cachexia necessitates the incorporation of advanced imaging and molecular techniques to unravel the brain’s role in the syndrome. Functional MRI and neurochemical profiling, for instance, could delineate the alterations within motivational circuits, fostering targeted approaches to symptom management and rehabilitation.

Janowitz’s essay firmly establishes cachexia as a syndrome that transcends metabolic failure, positioning it as a critical interface of brain-body communication. By illuminating the neurobiological underpinnings, the work not only enhances scientific understanding but also carries profound implications for improving patient care and outcomes across oncology and chronic disease management.

In conclusion, Of Hope from Fading Will is a pivotal contribution to science that reframes cachexia within the contexts of neuroscience and immunology. It encourages a holistic view of disease that values the narratives of patients as drivers of discovery and innovation. Ultimately, this reconceptualization offers hope for novel therapies that can restore vitality and agency to individuals wrestling with the debilitating grip of cachexia.

Subject of Research: Cachexia neurobiology and interoceptive signaling in cancer patients

Article Title: Of Hope from Fading Will: Interoceptive Signaling and the Behavioral Biology of Cachexia

News Publication Date: 3-Sep-2025

Web References:
DOI link to the article
Cold Spring Harbor Laboratory Researcher Tobias Janowitz
Link between brain and immune system in cachexia

References:
Janowitz, T. (2025). Of Hope from Fading Will: Interoceptive Signaling and the Behavioral Biology of Cachexia. Neuron. https://doi.org/10.1016/j.neuron.2025.06.019

Image Credits: Cold Spring Harbor Laboratory

Keywords: Cachexia, Cancer Research, Neuroscience, Metabolic Disorders, Neural Pathways, Immunology